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Background: Combinations of trastuzumab with either docetaxel or vinorelbine are considered valuable treatment
options for HER2-positive metastatic breast cancer patients. We performed a retrospective comparison of the
clinical outcomes associated with either one of these combinations.
Methods: From a multi-institutional database we retrieved 179 patients treated with either docetaxel or
vinorelbine plus trastuzumab as first-line therapy for HER2-positive advanced breast cancer.
Results: Docetaxel-trastuzumab was superior to vinorelbine-trastuzumab in terms of response rate (RR: 77 vs 57%,
p = 0.01) and median overall survival (OS: 35 vs 23 months, p = 0.04), but not in median time to progression (TTP:
12 vs 10 months, p = 0.53). At multivariate analysis, type of treatment was not associated with TTP but was an
independent predictor of OS, with a significant reduction in the risk of death in favor of docetaxel-trastuzumab (HR
0.474, 95% IC 0,303-0.742, p < 0.01).
Conclusion: Docetaxel or vinorelbine, when combined with trastuzumab, provide excellent rates of tumor control
in patients with previously untreated HER2-positive advanced breast cancer. Docetaxel may offer some advantage
in terms of response rate and resulted in a significantly prolonged overall survival, which, because of the
retrospective design of our study, deserves further investigation in prospective trials.
Background
Trastuzumab, a monoclonal antibody directed against
HER2, the product of the c-erbB2 proto-oncogene,
represents a major step forward in the treatment of the
subset of 20 to 30% human breast cancers carrying this
genetic abnormality[1-4]. The combination of trastuzu-
mab and chemotherapy resulted in improved clinical
outcomes, compared with chemotherapy alone, in
patients with HER2-positive advanced breast cancer[1,2].
On account of the pivotal trial[1] and of a subsequent
randomized phase II study (M77001)[2], this monoclo-
nal antibody was registered for the treatment of HER2-
positive advanced breast cancer patients in combination
with the taxanes paclitaxel and docetaxel.
Based on preclinical observations suggesting additivity
or even synergism between trastuzumab and other com-
monly used cytotoxic agents[5,6], several phase II clini-
cal trials have been subsequently conducted testing
different associations. Vinorelbine, a vinca-alkaloid deri-
vative, has shown a remarkable clinical activity in
anthracycline pre-treated advanced breast cancer
patients[7-9]. Preclinical synergism between vinorelbine
and trastuzumab was apparently confirmed in the clinic.
Response rates of up to 84% response rates were
reported when vinorelbine and trastuzumab were used
as first-line treatment in appropriately selected HER2-
positive advanced breast cancer patients[10,12,13]. For
these reasons, together with the favorable toxicity profile
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alternative to taxanes in combination with trastuzumab.
To date, the choice between a taxane or vinorelbine as a
companion for trastuzumab in the first-line treatment of
HER2-positive metastatic breast cancer does not rely on
data from direct comparisons. A single trial, which failed
i t st a r g e ta c c r u a l ,i sa v a i l a b l et h a ts o u g h tt oc o m p a r e
first-line trastuzumab with vinorelbine or with taxane-
based therapies[14]. Although it may be reassuring that
in the 81 out of the projected 250 patients that could be
randomized no significant differences in the main clini-
cal outcomes were observed, this trial can hardly be
considered conclusive with respect to its main objec-
tives. Apart from premature closure, another limitation
of this trial is that patients in the taxane based arm
received heterogeneous paclitaxel and docetaxel-based
combinations.
Due to the potential relevance of the issue of the
optimal combination of chemotherapy with trastuzu-
mab and the lack of solid evidence from prospective
trials, we undertook a retrospective comparison of
trastuzumab with either docetaxel or vinorelbine as
first-line treatment for HER2-positive advanced breast
cancer.
Patients and methods
Patients for this analysis were selected from a multi-
institutional database containing the clinical data of
women with HER2-positive breast cancer receiving tras-
tuzumab-based therapy for metastatic disease and trea-
ted at 11 different Institutions in Italy, United Kingdom
and Hungary. Investigators at each site were asked to
provide data for all the consecutive patients who
received at least one infusion of trastuzumab for the
treatment of metastatic breast cancer, together with
their clinical and pathological characteristics, prior treat-
ments for breast cancer and details of the first trastuzu-
m a b - b a s e dt r e a t m e n t( d r u g sa n dd o s e s ,b e s tt u m o r
response, date of further progression, and date of death
or of last follow-up visit). As of October 31
st 2008 the
database contained clinical data of 441 patients. We
queried the database in order to select patients who had
received trastuzumab with either docetaxel or vinorel-
bine as first-line treatment for HER2-positive disease.
Patients selected for this analysis could have received
endocrine therapy for metastatic disease but not prior
chemotherapy other than in the adjuvant or neoadjuvant
setting. HER2 positivity was defined as 3+ score by
immunohistochemistry (IHC) using the HercepTest. In
t h ec a s eo f2 +s c o r ea tI H C ,t h ec o n f i r m a t i o no fH E R 2
gene amplification by Fluorescence in situ hybridization
(FISH) was required. All patients had their specimens
centrally reviewed for HER2 status by the HercepTest
and, when required, by FISH analysis.
For patients with measurable metastatic disease, we
asked the investigators to assess and report tumor
response according to the WHO criteria[15]. No centra-
lized review of diagnostic imaging was performed to
confirm the tumor responses reported by investigators.
Response rate was defined as the proportion of patients
achieving complete or partial remission (CR+PR). Time
to progression (TTP) and overall survival (OS) were cal-
culated by the Kaplan Meier method for the overall
dataset of patients (intent-to-treat analysis) from the
date of the first administration of trastuzumab to the
date of tumor progression or death by any cause (TTP),
or to the date of death (OS).
Patients who were alive were censored at the date of
the last follow-up contact. Comparisons between
patients characteristics were studied by the Chi Square
or the Fischer’s exact test for dichotomous variables,
and by the Mann Whitney U test for continuous vari-
ables. Survival curves were compared by the log-rank
test. Additionally, the impact of type of treatment (doce-
taxel or vinorelbine) and other variables on TTP and
OS was studied by Cox Proportional Hazards Analysis.
Statistical significance was set at p < 0.05. All the ana-
lyses were conducted by the SPSS 15.0 statistical
package.
Being a retrospective analysis of clinical outcomes, no
specific written informed consent was required for this
study. However, the process of data collection was con-
ducted in compliance with the Ethical requirements of
each of the participating Institutions.
Results
Patients and treatments
A total of 178 women with HER2-positive metastatic
breast cancer (IHC 3+ or FISH positive) started trastu-
zumab with either docetaxel (106) or vinorelbine (72) as
first-line treatment between September 1999 and June
2008. Main patient characteristics according to type of
chemotherapy are summarized in table 1. Significant
imbalances in the two groups were found for stage of
disease at first diagnosis of breast cancer, with more
patients with stage IV in the docetaxel group, for lung
and soft tissue involvement, which again were more fre-
quent in the docetaxel group. Prior exposure to taxanes
in the adjuvant setting was more frequent in the vinorel-
bine group. Differences of borderline statistical signifi-
c a n c ew e r ea l s of o u n df o rH E R 2s t a t u sa tI H C ,w h i c h
was more frequently 3+ in the vinorelbine group, and
for visceral involvement and ≥ 3 metastatic sites, which
were more frequent in the docetaxel group.
Docetaxel was always administered every 3-weeks, at
doses per-cycle ranging from 75 to 100 mg/m
2,a n d
continued for 6 to 8 cycles. Patients achieving at least
SD continued with trastuzumab alone as maintenance
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tered weekly, usually at the dose of 25 mg/m
2,w a s
planned to be continued with trastuzumab until tumor
progression or unacceptable toxicity. The median num-
ber of administered cycles of docetaxel was 6 (range
1-8). The median number of weekly doses of vinorelbine
was 38 (range 3-52).
Analysis of tumor response
A total of 166 patients had measurable metastatic dis-
ease and could be evaluated for tumor response. Tumor
responses according to type of treatment, as reported
by each investigator at each site, are summarized in
table 2.
The combination of docetaxel and trastuzumab
resulted in superior ORR (77 vs 57%, p = 0.01), which
was mainly due an increase in the partial remission rate.
Twelve and thirteen patients in the docetaxel and vinor-
elbine group respectively, achieved a disease stabilization
that lasted at least 6 months. The resulting clinical ben-
efit rate was 89% and 76% for docetaxel and vinorelbine,
respectively (p = 0.07).
Table 1 Patients characteristics according to type of chemotherapy added to trastuzumab
Docetaxel (106) Vinorelbine (72) P
Median Age, years (range) 55 (33-73) 54 (29-81) 0.47
HER2 Status 0.05
IHC 3+ 86 (81%) 66 (92%)
IHC 2+
1 20 (19%) 6 (8%)
ER positive
2 50 (47%) 32 (44%) 0.63
PgR positive
3 34 (32%) 22 (31%) 0.64
Initial disease Stage
4 < 0.01
I 12 (11%) 7 (10%)
II and III 71 (67%) 58 (80%)
IV 23 (22%) 6 (8%)
Prior adjuvant/neoadjuvant chemotherapy 70 (66%) 55 (76%) 0.14
Prior exposure to anthracycline
5 62 (58%) 50 (69%) 0.14
Prior exposure to taxanes
5 16 (15%) 31 (43%) < 0.01
Prior endocrine therapy
6 43 (40%) 35 (49%) 0.24
Median DFS in months (range)
7 21 (0-136) 24 (0-146) 0.33
Sites of metastatic disease
Liver 58 (55%) 33 (46%) 0.24
Lung 43 (41%) 18 (25%) 0.03
Bone 46 (43%) 30 (42%) 0.82
Soft-tissue/nodes 71 (67%) 37 (51%) 0.04
Central nervous system 4 (4%) 3 (4%) 0.90
Visceral involvement (lung + liver + CNS) 82 (77%) 47 (65%) 0.08
Number metastatic sites 0.09
1 31 (29%) 28 (39%)
2 30 (28%) 25 (35%)
≥ 3 45 (42%) 19 (26%)
Table 2 Tumor response according chemotherapy associated with trastuzumab (166 evaluable patients)
1
Docetaxel + Trastuzumab N = 99 95% C.I. Vinorelbine + Trastuzumab N = 67 95% C.I. P*
ORR (CR+PR) 76 (77%) 68%-84% 38 (57%) 45%-68% 0.01
CR 16 (16%) 10 (15%)
PR 60 (61%) 28 (42%)
SD 18 (18%) 17 (25%)
PD 5 (5%) 12 (18%)
CBR (CR+PR+SD ≥ 6 months) 88 (89%) 81%-94% 51 (76%) 65%-85% 0.07
Abbreviations: C.I., confidence interval: RR, response rate: CR, complete remission: PR, partial remission: SD, stable disease: PD, progressing disease: CBR, clinical
benefit rate
1For 12 patients (7 receiving docetaxel and 5 receiving vinorelbine) tumor response was not available at the time of the analysis
*Chi square test.
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All 178 patients were included in the survival analyses.
The median follow-up for patients who were alive at the
time of this analysis was 21 months (range 6-81) and 18
months (range 5-71) for patients receiving trastuzumab
with docetaxel or vinorelbine, respectively. In the former
group, a total of 80 patients experienced disease progres-
sion and 55 died. In the group of patients receiving vinor-
elbine and trastuzumab, a total of 57 experienced disease
progression and 39 died. The Kaplan Meyer estimates of
TTP and OS according to type of treatment are displayed
in figures 1 and 2. There was no significant difference in
median TTP according to treatment type (12 vs 10
months for docetaxel plus trastuzumab and vinorelbine
plus trastuzumab, respectively, p = 0.53). Median OS,
however, differed significantly in favor of the docetaxel-
treated group, with a 12-month gain (35 vs 23 months
for docetaxel plus trastuzumab and vinorelbine plus tras-
tuzumab, respectively, p = 0.04).
We then fitted Cox Proportional Regression models of
TTP and OS including the following covariates together
with type of chemotherapy added to trastuzumab:
patient age, which was dichotomized around its overall
median value of 55 years, disease-free survival (DFS)
from the diagnosis of primary breast cancer to the diag-
nosis of metastatic disease, which was dichotomized
around its overall median value of 21 months, hormone
receptor status, HER2 status (3+ vs 2+/FISH positive),
receipt of prior adjuvant or neoadjuvant chemotherapy,
prior treatment with anthracyclines, prior treatment
with taxanes, prior exposure to endocrine therapy, pat-
tern of metastatic disease (liver vs other sites), number
of metastatic sites (1 vs 2 vs ≥ 3). All the variables,
regardless of their significance at univariate analysis,
were included into a saturated model and then removed
one at a time through a backward elimination selection
method using the Wald test at a significance level of
p < 0.05. Results of the multivariate analysis are sum-
marized in table 3.
Disease-free interval < 21 months, liver involvement
and multiple sites of metastatic disease were significantly
associated with worse DFS. In the model including these
Figure 1 Kaplan-Meier estimate of time to progression according to type of chemotherapy associated with trastuzumab. The solid
line represents patients receiving docetaxel and the dashed line those receiving vinorelbine.
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Page 4 of 9Figure 2 Kaplan-Meier estimate of overall survival according to type of chemotherapy associated with trastuzumab. The solid line
represents patients receiving docetaxel and the dashed line those receiving vinorelbine.
Table 3 Multivariate Cox-Proportional Hazard analysis of factors associated with TTP and OS
TTP OS
Variable HR 95% C.I. P HR 95% C.I. P
Type of treatment
Vinorelbine 1.0 1.0
Docetaxel 0.765 0.538-1.087 0.14 0.474 0.303-0.742 < 0.01
DFI
≥ 21 months 1.0 1.0
< 21 months 1.546 1.092-2.189 0.01 1.945 1.249-3.029 < 0.01
Liver involvement
No 1.0 1.0
Yes 1.568 1.1084-2.268 0.02 1.925 1.186-3.125 < 0.01
Number of involved sites
1 1.0 0.01
2 1.652 1.071-2.548 0.023 1.568 0.901-2.626 0.12
≥ 3 1.999 1.281-3.119 < 0.01 2.004 1.172-3.427 0.01
TTP, time to progression: OS, overall survival: C.I., confidence interval
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cant trend towards reduced risk of progression for
patients receiving docetaxel (table 3). The multivariate
analysis showed that the same factors predicting TTP
were also associated with worse OS and that docetaxel
was associated with a statistically significant reduction
in the risk of death (table 3).
Analysis of post-progression treatments and outcomes
Second-line treatment was known for 124 of 137
patients who progressed during first-line trastuzumab
plus either docetaxel or vinorelbine (table 4). Thirty-one
patients (38%) crossed over from docetaxel to vinorel-
bine-based treatments and 17 patients (30%) crossed
over from vinorelbine to a taxane. Eighteen patients
initially treated with docetaxel and 17 of those treated
with vinorelbine continued trastuzumab beyond disease
progression in addition to second-line chemotherapy. In
a total of 123 patients whose tumor response to second-
line therapy was available, the ORR was 24% and 31%
for those initially treated with trastuzumab with doce-
taxel or vinorelbine, respectively (p = 0.51). Median
time to progression during salvage chemotherapy was
7.7 months and 4.6 months for patients initially treated
with trastuzumab with docetaxel and vinorelbine,
respectively (p = 0.02, figure 3).
Discussion
In this retrospective comparison, the combination of
docetaxel and trastuzumab was associated with higher
response rate and longer overall survival compared
with vinorelbine and trastuzumab, with no differences
in time to progression. Obviously, because of retro-
spective nature of the study, several biases need to be
taken into account when interpreting our findings.
A major source of bias is the fact that the two popula-
tions were unbalanced with respect to factors that
could have potentially affected clinical outcomes. For
example, patients receiving docetaxel had more fre-
quently features of aggressive disease (more patients
with stage IV at first diagnosis of breast cancer, with
visceral involvement and with ≥ 3 metastatic sites). By
converse, patients in the vinorelbine group could be
considered relatively chemoresistant because of a more
frequent exposure to neo- or adjuvant chemotherapy,
and to taxanes in particular. Although we performed
multivariate analyses to correct the effect of treatment
by these potential covariates, the real impact of these
imbalances can not be estimated in this relatively small
cohort of patients. Another possible source of bias in
our study is the fact that no central revision of tumor
response was performed and timing and modality of
disease assessment might have been different according
to the Institution and the treating physician. In this
respect, the higher response rate in the docetaxel-tras-
t u z u m a bt r e a t e dg r o u pm u s tb ec o n s i d e r e dw i t h
caution.
The other relevant finding of our study was the overall
survival advantage in the docetaxel group. The endpoint
of mortality, which in our database is accurately col-
lected and constantly updated, is much less subject to
measurement bias than tumor response and time to
progression. We might be conservative and consider
also this finding as a possible result of the non-rando-
mized nature of our study.
In spite of that, we believe that this difference in over-
all survival is worth additional analysis. Studying sec-
ond-line options and outcomes, we found that time to
progression during salvage chemotherapy was signifi-
cantly longer in patients receiving docetaxel. This
possibly implies higher sensitivity to subsequent che-
motherapy in these patients, which could be the reason
for the improvement in survival. In our opinion, this
hypothesis could be true for two reasons, which are not
mutually exclusive. The first is that, as already discussed,
patients treated with vinorelbine had been more fre-
quently exposed to adjuvant chemotherapy and to tax-
anes in particular. This exposure may have resulted in
increased chemoresistance. The second reason is slightly
more speculative. The two regimens that were compared
differed in the duration of chemotherapy. All the
patients in the docetaxel group received this drug on a
3-weekly basis and for 6-8 cycles, beyond which single
agent trastuzumab was administered to non-progressing
patients. Conversely weekly vinorelbine was adminis-
tered with trastuzumab until tumor progression, result-
ing in longer duration of the combined treatment. If
this could have delayed tumor progression, it is also
possible that prolonged exposure to vinorelbine could
Table 4 Summary of second-line treatments
Initial Docetaxel + T Initial Vinorelbine + T
Treatment N 80 (T)
1 N 57 (T)
1
Vinorelbine-based 31 (15) 3 (1)
Paclitaxel-based 1 (0) 11 (7)
Docetaxel-based 3 (2) 6 (3)
Capecitabine-based 6 (1) 12 (4)
Trastuzumab
2 10 6
Anthracycline-based 6 (0) 3 (0)
Endocrine therapy 9 (5) 1 (0)
Miscellaneous 3 (0) 7 (2)
Best supportive care 3 (0) 3 (0)
Treatment not detailed 8 5
1Number in parentheses indicate the number of patients who continued
trastuzumab beyond disease progression in addition to chemotherapy or
endocrine therapy
2Patients receiving trastuzumab alone had isolated central nervous system
progression and were managed with radiation therapy.
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tant phenotype[16], which limited the efficacy of subse-
quent salvage therapy.
Recently published guidelines indicate both docetaxel
and vinorelbine among the preferred first-line agents
with trastuzumab despite the absence of randomized
comparisons among different combinations[17]. If, on
one hand, this implies an assumption of equal efficacy,
on the other hand it points at toxicity and convenience
as factors to guide therapeutic choices. Unfortunately,
we were not able to collect accurate safety data in our
study. However, differences between docetaxel and
vinorelbine in combination with trastuzumab can be
derived from the medical literature and from our pre-
vious published experience[2,10,18,19]. Docetaxel
is more frequently associated with grade 3 and 4
neutropenia, febrile neutropenia, thrombocytopenia (all
grades), alopecia, fluid retention, nail changes and per-
ipheral neuropathy. By converse, vinorelbine, is more
frequently associated with constipation and gastrointest-
inal disorders. Overall, the docetaxel-trastuzumab
regimen is, in fact, more toxic than vinorelbine-trastuzu-
mab. Therefore, it is reasonable to prefer vinorelbine
and trastuzumab, as many oncologists do, if the assump-
tion of equal efficacy is true. However, we believe that
our results, together with those of a randomized study
in the adjuvant setting, [2 0 ]s e e mt oc h a l l e n g et h i s
assumption.
In high-risk, operable breast cancer patients, docetaxel
followed by FEC (5-fluorouracil, epirubicin and cyclo-
phosphamide) outperformed vinorelbine followed by
FEC, with a 42% proportional reduction in the hazard of
Figure 3 Kaplan-Meier estimates of time to second progression, measured from the date of second-line therapy initiation to that of
tumor progression or death in the absence of progression in patients whose initial treatment was docetaxel plus trastuzumab (solid
line) or vinorelbine plus trastuzumab (dashed line). The analysis is based on 69 and 49 events occurring in 80 and 57 patients who had
initially received trastuzumab with docetaxel or vinorelbine, respectively.
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also randomized patients with HER2-positive disease to
9 weeks of trastuzumab given concomitantly with doce-
taxel or vinorelbine. A recent update of this study con-
firmed that the addition of trastuzumab to docetaxel,
but not to vinorelbine, yielded a significant benefit in
terms of time to distant relapse[21].
Based on our findings of an increased overall survival
in patients receiving docetaxel-trastuzumab, we believe
that the issue of optimal companion cytotoxic agent for
trastuzumab in first-line regimens for HER2-positive
metastatic breast cancer is worthy of further investiga-
tion in adequately designed prospective trials.
Conclusions
Our retrospective analysis confirms that both docetaxel
and vinorelbine, when combined with trastuzumab, pro-
vide excellent rates of tumor control in patients with
HER2-positive advanced breast cancer. With the
increasing number of women receiving docetaxel and
trastuzumab as part of adjuvant treatment, our data pro-
vide reassurance on combinations of vinorelbine and
trastuzumab as first-line option for recurring patients.
At the likely price of increased toxicity, docetaxel may
offer some advantage in terms of response rate and
resulted in a significantly prolonged overall survival,
which deserves further investigation.
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